CURRENT CONCEPTS IN RADIOTHERAPY FOR BENIGN DISORDERS

CurrentConceptsinRadiotherapyforBenignDisorders1-0-25kapak

Dupuyten’s Contracture and Peyronie Disease

Fatma SERTa , Serra KAMERa
aEge University Faculty of Medicine, Department of Radiation Oncology, İzmir, Türkiye

Sert F, Kamer S. Dupuyten’s contracture and peyronie diseas. In: Uysal B, Gamsız H, eds. Current Concepts in Radiotherapy for Benign Disorders. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.22-7.

ABSTRACT
Radiotherapy (RT) is one of the main treatment modalities that has been used in the treatment of benign and malign diseases. Dupuytren’s Contracture (DC) is a benign yet progressive fibrotic condition affecting the hand and digits, resulting in flexion deformities that can be significantly disabling for some patients. The primary approach to treatment remains watchful waiting during the early and stable phases of the disease. RT may also be relevant for patients who experience rapid progression or early relapse after surgery, assuming that myofibroblasts and proliferating fibroblasts. Peyronie’s disease (PD), also known as induratio penis plastica, was named after François Gigot de la Peyronie, a renowned French surgeon who contributed significantly to the principles of modern intestinal surgery. RT in the early stages of PD using low doses(12-15 Gy) is effective to treat penile pain in more than 80% of patients and reduces penile curvature in up to 64% of patients.

Keywords: Dupuytren contracture; penile induration; radiotherapy; neoplasms

Referanslar

  1. van Rijssen AL, Werker PMN. treatment for Dupuytren's disease: an overview of options. In: Eaton C, Seegenschmiedt MH, Bayat A, Gabbiani G, Werker P, Wach W, eds. Dupuytren's Disease and related Hyperproliferative Disorders: Principles, research, and Clinical perspectives. 1st ed. Springer Berlin, Heidelberg; 2012. p.35-43.
  2. Adamietz B, Keilholz L, Grtinert J, Sauer R. Radiotherapy in early stage Dupuytren's contracture. Strahlenther Onkol. 2001;177:604-10. [Crossref]  [PubMed]
  3. Millesi H. Dupuytren-contraktur. In: Nigst H, Buck-Gramcko D, Millesi H, eds. Handchirurgie, Band I. Allgemeines, Wahloperationen. Stuttgart New York: Thieme; 1981. p. 15.01-15.57
  4. Murrell GAC, Francis MJO, Howlett CR. Dupuytren's contracture, fine structure in relation to aetiology. J Bone Joint Surg. 1989;71B:367-72. [Crossref]  [PubMed]
  5. Hueston JT. Dupuytren's Contracture. Baltimore: Williams &Wilkins; 1963. [Crossref]  [PubMed]
  6. Murell GAC, Francis MJO, Bromley L. Free radicals and Dupuytren's contracture. Br Med J. 1987;295:1373-5. [Crossref]  [PubMed]  [PMC]
  7. Murrell GAC, Francis MJO, Bromley L. Modulation of fibroblast proliferation by oxygen free radiacals. Biochem J. 1990;165:659-65. [Crossref]  [PubMed]  [PMC]
  8. Denkler KA, Park KM, Alser O. treatment options for Dupuytren's Disease: tips and tricks. plast reconstr Surg Glob Open. 2022;10(1):e4046. [Crossref]  [PubMed]  [PMC]
  9. Rayan GM. Nonoperative treatment of Dupuytren's disease. J Hand surg am. 2008;33:1208-10. [Crossref]  [PubMed]
  10. Turesson C. The role of hand therapy in Dupuytren disease. Hand Clin. 2018;34:395-401. [Crossref]  [PubMed]
  11. Rodemann HP, Bamberg M. Cellular basis of radiation induced fibrosis. radiother oncol. 1995;35:83-90. [Crossref]  [PubMed]
  12. Rodemann HP, Peterson HP, Schwenke K, von Wangenheim KH. Terminal differentiation of human skin fibroblasts is induced by radiation. Scand Microsc. 1991;5:1135-43.
  13. Rubin P, Soni A, Williams JP. The molecular and cellular biologic basis for radiation treatment of benign proliferative diseases. Sem Rad Oncol. 1999; 9:203-14. [Crossref]  [PubMed]
  14. Terek RM, Jiranek WA, Goldberg MJ, Wolfe HJ, Alman BA. The expression of plateletderived growthfactor gene in Dupuytren contracture. J Bone Joint Surg. 1995;77a:1-9. [Crossref]  [PubMed]
  15. Tomasek J, Rayan GM. Correlation ofalpha-smooth muscle actin expression and contraction in Duputren's disease fibroblasts. J Hand surg am. 1995; 20:450-5. [Crossref]  [PubMed]
  16. Smitt MC, Donaldson SS. Radiation therapy for benign disease of the orbit. Sem Rad Oncol. 1999;9:179-89. [Crossref]  [PubMed]
  17. Seegenschmiedt MH, Attassi M. Strahlentherapie beim Morbus Ledderhose-Indikation und Ergebnisse. Strahlenther Onkol. 2003;179(12):847-53. [Crossref]  [PubMed]
  18. Seegenschmiedt MH, Keilholz L, Wielpütz M, Schubert C, Fehlauer F. Long-term outcome of radiotherapy for early stage Dupuytren's disease: a phase III clinical study. Dupuytren's Disease and Related Hyperproliferative Disorders: Principles, Research, and Clinical Perspectives. 2012;349-71. [Crossref]
  19. De La Peyronie FG. Sur quelques obstacles qui s'opposent~ l'ejaculation naturelle de la semence. Mem Acad R Chir. 1743;1:425-34.
  20. Hauck EW, Weidner W. Franqois de la Peyronie and the disease named after him. Lancet. 2001;357:2049-51. [Crossref]  [PubMed]
  21. La Pera G, Pescatori ED, Calabrese M, Boffini A, Colombo F, Andrianiet e, al. peyronie's disease: prevalence and association with cigarette smoking. Eur Urol. 2001;40:525-30. [Crossref]  [PubMed]
  22. Larow P, Lowe FC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. Urol. 1997;158:1388-90. [Crossref]  [PubMed]
  23. Schiavino D, Sasso F, Nucera E, Alcini E, Gulino G, Milani a,et al. Immunologic findings in Peyronie's disease: a controlled study. Urology. 1997;50:764-8. [Crossref]  [PubMed]
  24. Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol. 1997;157:311-5. [Crossref]
  25. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int. 2003;91(9):830-8. [Crossref]  [PubMed]
  26. Fricke RE, Olds W. The radium treatment of Peyronie's disease. AIR. 1939; 42:545-50.
  27. Furlow WL, Swenson He Jr, Lee RE. Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol. 1975;114(1):69-71. [Crossref]  [PubMed]
  28. Mira JG, Chahbazian CM, del Regato JA. The value of radiotherapy for peyronie's disease: presentation of 56 new case studies and review of the literature. Int J Radiat Oncol Biol Phys. 1980;6(2):161-6. [Crossref]  [PubMed]
  29. Incrocci L, Wijnmaalen A, Slob AK, et al. Low-dose radiotherapy in 179 patients with Peyronie's Disease: treatment outcome and current sexual functioning. Int J Radiat Oncol Biol Phys. 2000a;47:1353-6. [Crossref]  [PubMed]
  30. Incrocci L, Hop WCJ, Slob AK. Current sexual functioning in 106 patients with peyronie's disease, treated with radiotherapy 9 years earlier. Urology. 2000b; 56:1030-4. [Crossref]  [PubMed]
  31. Hall SJ, Basile G, Bertero EB, et al. Extensive corporeal fibrosis after penile irradiation. J Urol. 1995;153:372-7. [Crossref]  [PubMed]